ATAI Life Sciences NV (FRA:9VC) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Days Payable?

ATAI Life Sciences NV's average Accounts Payable for the three months ended in Mar. 2024 was €3.87 Mil. ATAI Life Sciences NV's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil.

The historical rank and industry rank for ATAI Life Sciences NV's Days Payable or its related term are showing as below:

FRA:9VC's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

ATAI Life Sciences NV's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

ATAI Life Sciences NV Days Payable Historical Data

The historical data trend for ATAI Life Sciences NV's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Days Payable Chart

ATAI Life Sciences NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

ATAI Life Sciences NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of ATAI Life Sciences NV's Days Payable

For the Biotechnology subindustry, ATAI Life Sciences NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ATAI Life Sciences NV's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Days Payable distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Days Payable falls into.

ATAI Life Sciences NV Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ATAI Life Sciences NV's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.265	+	4.208)	/	2 )	/	0	*	365
=	3.2365					/	0	*	365
=	N/A

ATAI Life Sciences NV's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (4.208	+	3.536)	/	2 )	/	0	*	365 / 4
=	3.872					/	0	*	365 / 4
=	N/A

ATAI Life Sciences NV Days Payable Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV (FRA:9VC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ATAI:USA ATAI:Mexico

Address

Wallstraße 16, Berlin, BB, DEU, 10179

Website

https://www.atai.life

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV (FRA:9VC) Headlines

No Headlines